NR-566 ADVANCED
PHARMACOLOGY –
MIDTERM EXAM
Section 1: Pharmacokinetics & Pharmacodynamics
1. Which process describes what the body does to a drug, including absorption,
distribution, metabolism, and excretion?
A. Pharmacodynamics
B. Pharmacogenetics
C. Pharmacokinetics
D. Pharmacotherapeutics
Rationale: Pharmacokinetics (PK) refers to the movement of a drug through the body—
what the body does to the drug. Pharmacodynamics is what the drug does to the body.
Pharmacogenetics studies genetic influences on drug response, and
pharmacotherapeutics focuses on clinical use of drugs in disease treatment .
2. A patient with a low serum albumin level is prescribed a highly protein-bound
drug. What is the main concern for this patient?
A. Rapid renal excretion
B. Decreased therapeutic effect
C. Increased risk of drug toxicity
D. Reduced drug absorption
,Rationale: Low albumin means fewer binding sites, leading to more free (active) drug in
the bloodstream, which increases the risk of toxicity. This is especially important for
highly protein-bound drugs like phenytoin and warfarin .
3. Which enzyme system in the liver is most commonly responsible for the
metabolism of the majority of drugs?
A. MAO system
B. Cholinesterase system
C. Glucuronidation system
D. Cytochrome P450 system
Rationale: The Cytochrome P450 (CYP450) enzyme system is the primary pathway for
hepatic drug metabolism. CYP3A4 alone is responsible for metabolizing approximately
50–60% of clinically used drugs .
4. Which of the following describes the "First-Pass Effect"?
A. Rapid renal clearance of a drug after the first dose
B. The binding of a drug to plasma proteins
C. Metabolism of an oral drug in the liver before reaching systemic circulation
D. The time it takes for a drug to reach steady state
Rationale: Oral drugs are absorbed in the GI tract and pass through the liver via the
portal vein, where they may be significantly metabolized before entering systemic
circulation. This reduces bioavailability .
5. How many half-lives does it typically take for a drug to reach steady-state
concentration?
A. 1 to 2
B. 2 to 3
,C. 4 to 5
D. 7 to 10
Rationale: It generally takes 4 to 5 half-lives for a drug to reach a plateau or steady-
state concentration in the plasma. For a drug with a 24-hour half-life, steady state is
reached in about 4–5 days .
6. A drug has a half-life of 36 hours. Approximately how many days will it take to
reach steady state?
A. 2–3 days
B. 5–7 days
C. 7–10 days
D. 10–14 days
Rationale: Steady state is achieved after 4–5 half-lives. With a 36-hour half-life, steady
state occurs in approximately 7–10 days (36 hours × 5 = 180 hours ≈ 7.5 days) .
7. Which statement best describes a non-competitive antagonist?
A. It binds reversibly to the same receptor site as the agonist.
B. It binds irreversibly to the receptor or allosterically, reducing the maximal
response.
C. It produces the same maximal response as the agonist.
D. It enhances the effect of the agonist.
Rationale: A non-competitive antagonist binds irreversibly or allosterically, reducing the
maximal response (efficacy) of the agonist. It cannot be overcome by increasing agonist
concentration, unlike a competitive antagonist .
8. Which statement best describes a competitive antagonist?
, A. It binds irreversibly to the receptor and causes permanent inactivation.
B. It binds to the same receptor site as the agonist and reversibly blocks it.
C. It binds to a different receptor site and enhances the agonist's effect.
D. It produces the same maximal response as the agonist.
Rationale: A competitive antagonist reversibly binds to the same receptor site as the
agonist, preventing the agonist from binding. Its effects can be overcome by increasing
the concentration of the agonist .
Section 2: Pharmacogenomics & Individual Variation
9. A patient is a CYP2C19 poor metabolizer. Which medication would have reduced
efficacy due to impaired activation?
A. Omeprazole
B. Clopidogrel
C. Amoxicillin
D. Propranolol
Rationale: Clopidogrel is a prodrug requiring CYP2C19-mediated activation. Poor
metabolizers have reduced conversion to the active metabolite, increasing risk of
thrombotic events. Alternative antiplatelet therapy should be considered .
10. Which genetic variation is associated with an increased risk of abacavir
hypersensitivity reaction?
A. HLA-B*5701
B. HLA-B*5801
C. CYP2C9*2
D. VKORC1
Rationale: HLA-B*5701 screening is required before abacavir initiation. Patients positive
for this allele are at high risk for hypersensitivity and should not receive abacavir .
PHARMACOLOGY –
MIDTERM EXAM
Section 1: Pharmacokinetics & Pharmacodynamics
1. Which process describes what the body does to a drug, including absorption,
distribution, metabolism, and excretion?
A. Pharmacodynamics
B. Pharmacogenetics
C. Pharmacokinetics
D. Pharmacotherapeutics
Rationale: Pharmacokinetics (PK) refers to the movement of a drug through the body—
what the body does to the drug. Pharmacodynamics is what the drug does to the body.
Pharmacogenetics studies genetic influences on drug response, and
pharmacotherapeutics focuses on clinical use of drugs in disease treatment .
2. A patient with a low serum albumin level is prescribed a highly protein-bound
drug. What is the main concern for this patient?
A. Rapid renal excretion
B. Decreased therapeutic effect
C. Increased risk of drug toxicity
D. Reduced drug absorption
,Rationale: Low albumin means fewer binding sites, leading to more free (active) drug in
the bloodstream, which increases the risk of toxicity. This is especially important for
highly protein-bound drugs like phenytoin and warfarin .
3. Which enzyme system in the liver is most commonly responsible for the
metabolism of the majority of drugs?
A. MAO system
B. Cholinesterase system
C. Glucuronidation system
D. Cytochrome P450 system
Rationale: The Cytochrome P450 (CYP450) enzyme system is the primary pathway for
hepatic drug metabolism. CYP3A4 alone is responsible for metabolizing approximately
50–60% of clinically used drugs .
4. Which of the following describes the "First-Pass Effect"?
A. Rapid renal clearance of a drug after the first dose
B. The binding of a drug to plasma proteins
C. Metabolism of an oral drug in the liver before reaching systemic circulation
D. The time it takes for a drug to reach steady state
Rationale: Oral drugs are absorbed in the GI tract and pass through the liver via the
portal vein, where they may be significantly metabolized before entering systemic
circulation. This reduces bioavailability .
5. How many half-lives does it typically take for a drug to reach steady-state
concentration?
A. 1 to 2
B. 2 to 3
,C. 4 to 5
D. 7 to 10
Rationale: It generally takes 4 to 5 half-lives for a drug to reach a plateau or steady-
state concentration in the plasma. For a drug with a 24-hour half-life, steady state is
reached in about 4–5 days .
6. A drug has a half-life of 36 hours. Approximately how many days will it take to
reach steady state?
A. 2–3 days
B. 5–7 days
C. 7–10 days
D. 10–14 days
Rationale: Steady state is achieved after 4–5 half-lives. With a 36-hour half-life, steady
state occurs in approximately 7–10 days (36 hours × 5 = 180 hours ≈ 7.5 days) .
7. Which statement best describes a non-competitive antagonist?
A. It binds reversibly to the same receptor site as the agonist.
B. It binds irreversibly to the receptor or allosterically, reducing the maximal
response.
C. It produces the same maximal response as the agonist.
D. It enhances the effect of the agonist.
Rationale: A non-competitive antagonist binds irreversibly or allosterically, reducing the
maximal response (efficacy) of the agonist. It cannot be overcome by increasing agonist
concentration, unlike a competitive antagonist .
8. Which statement best describes a competitive antagonist?
, A. It binds irreversibly to the receptor and causes permanent inactivation.
B. It binds to the same receptor site as the agonist and reversibly blocks it.
C. It binds to a different receptor site and enhances the agonist's effect.
D. It produces the same maximal response as the agonist.
Rationale: A competitive antagonist reversibly binds to the same receptor site as the
agonist, preventing the agonist from binding. Its effects can be overcome by increasing
the concentration of the agonist .
Section 2: Pharmacogenomics & Individual Variation
9. A patient is a CYP2C19 poor metabolizer. Which medication would have reduced
efficacy due to impaired activation?
A. Omeprazole
B. Clopidogrel
C. Amoxicillin
D. Propranolol
Rationale: Clopidogrel is a prodrug requiring CYP2C19-mediated activation. Poor
metabolizers have reduced conversion to the active metabolite, increasing risk of
thrombotic events. Alternative antiplatelet therapy should be considered .
10. Which genetic variation is associated with an increased risk of abacavir
hypersensitivity reaction?
A. HLA-B*5701
B. HLA-B*5801
C. CYP2C9*2
D. VKORC1
Rationale: HLA-B*5701 screening is required before abacavir initiation. Patients positive
for this allele are at high risk for hypersensitivity and should not receive abacavir .
